Geographic Atrophy Market Size Forecasted To Achieve $3.5 Billion By 2029 With Steady Growth

The Geographic Atrophy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Geographic Atrophy Market Size and Projected Growth Rate?
The market size for geographic atrophy has experienced rapid expansion in recent years, with forecasts predicting an increase from $1.86 billion in 2024 to $2.12 billion in 2025, marking a compound annual growth rate (CAGR) of 13.7%. Factors contributing to this historical growth include an aging population, a surge in demand for innovative treatment solutions, a higher incidence of geographic atrophy, heightened health consciousness, and an uptick in cases of retinal diseases.

Over the coming years, the market size for geographic atrophy is projected to experience rapid growth, reaching $3.50 billion by 2029 with a compound annual growth rate (CAGR) of 13.5%. This expected surge over the forecast period can be credited to amplified focus on research and development, intensified R&D investments, the growing use of smartphones, increased healthcare spending, and greater investments in clinical trials. Key trends anticipated during the forecast period involve progress in gene therapy, healthcare technology advancements, the creation of innovative technologies, the rise in telemedicine, and the development of novel and effective medications.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21984

What Are the Major Segments in the Geographic Atrophy Market?
The geographic atrophy market covered in this report is segmented -

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drugs
2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)
3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegmentss:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab
2) By Complement Inhibitors: Pegcetacoplan, Lfg316
3) By Neuroprotective Agents: Latanoprost, Brimonidine
4) By Other Drugs: Steroids, Retinoids, Combination Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

What Are The Driving Geographic Atrophy Market Evolution?
The anticipated surge in the incidence of age-related macular degeneration (AMD) is likely to fuel the expansion of the geographic atrophy market. AMD is an ocular ailment which impacts the central portion of the older adults' retinas, rendering them unable to discern finer details. The dominating factor for the increasing prevalence of AMD is the aging demographic, as the number of people living longer is rising and the natural process of aging leads to incremental damage to the eyes, making them progressively susceptible to the disease. Treatments for geographic atrophy help slow down retinal damage and conserve remaining vision for AMD patients. A case in point, a report released by Medical News Today, a US-based digital media firm, in January 2024 forecasts that global instances of AMD are set to increase from 196 million to 288 million by 2040. Consequently, the escalating frequency of AMD is stimulating the evolution of the geographic atrophy market.

Which Firms Dominate The Geographic Atrophy Market Segments?
Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics

What Trends Are Expected to Dominate the Geographic Atrophy Market in the Next 5 Years?
Leading businesses in the geographic atrophy market are turning their focus onto inventive therapies, such as complement inhibitor therapy, in their quest to pioneer advanced treatment methods for geographic atrophy. Complement inhibitor therapy is a kind of treatment that mitigates an excessively active immune response associated with certain diseases, protecting healthy cells from getting damaged and slowing down the progress of the disease. For instance, in February 2025, Astellas Pharma Inc., a pharmaceutical corporation based in Japan, made an announcement that the Food and Drug Administration, an agency of the US government, had approved IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy. This approval grants unlimited usage duration of IZERVAY for treating geographic atrophy (GA) resulting from age-related macular degeneration (AMD). This decision empowers more flexible management of GA and provides extended duration treatment alternatives for both patients and healthcare providers.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Which Is The Largest Region In The Geographic Atrophy Market?
North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Geographic Atrophy Market?
2. What is the CAGR expected in the Geographic Atrophy Market?
3. What Are the Key Innovations Transforming the Geographic Atrophy Industry?
4. Which Region Is Leading the Geographic Atrophy Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.